A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 546 participants.
Also called NCT06109311
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 546 participants
- Sponsor
- Registry
-
NCT06109311
-
- Other papers using this trial's data
- Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, China, Japan, Puerto Rico, Romania
- Registry status
- Completed
Technical summary
Registry record NCT06109311. Randomized; double masking; primary purpose treatment. Start 2023-11-10 (actual); primary completion 2025-09-15 (actual). Results posted on 2026-10-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
- Acronym
- ACHIEVE-5
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Orforglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06109311- Content hash
d4032d4d21e52991601b240af02604813da67159fef86a0f3af42b9dfae33410